QSHY Granules Promote White Adipose Tissue Browning and Correct BCAAs Metabolic Disorder in NAFLD Mice
Binbin Zhang,Mingzhu Ni,Xiaojing Li,Qiaohong Liu,Yiyang Hu,Yu Zhao
DOI: https://doi.org/10.2147/DMSO.S332659
2021-10-13
Abstract:Binbin Zhang, 1– 3 Mingzhu Ni, 1 Xiaojing Li, 1 Qiaohong Liu, 1 Yiyang Hu, 1, 4 Yu Zhao 1 1 Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China; 2 Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, People's Republic of China; 3 College of Life Sciences, Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang, People's Republic of China; 4 Institute of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China Correspondence: Yiyang Hu Institute of Clinical Pharmacology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528, Zhangheng Road, Shanghai, People's Republic of China Email Yu Zhao Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Institute of Liver Diseases, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528, Zhangheng Road, Shanghai, People's Republic of China Email Purpose: White adipose tissue (WAT) has positive effects on peripheral metabolism parameters and liver energy metabolism. This study aimed to explain the pharmacological mechanism of Qushi Huayu (QSHY) granules in the treatment of nonalcoholic fatty liver disease (NALFD) mice based on branched-chain amino acid (BCAA) catabolism and WAT browning. Patients and Methods: Thirty C57BL/6J mice were randomly divided into a (Ctrl) control group, fed with a control diet, a NAFLD model group, fed with a high-fat and high-sugar (HFHS) diet, and a QSHY granules treatment (HFHS+QSHY) group, administered with QSHY granules. After 14 weeks of feeding, HFHS+QSHY group mice were administered QSHY granules through oral gavage for 6 weeks. The metabolic parameters were assessed, the circular and fecal BCAA content was observed, and liver and epididymal WAT (eWAT) were collected for pathological, quantitative real-time polymerase chain reaction, and Western blotting analyses. Results: Compared with the HFHS group, mice in the HFHS+QSHY group demonstrated restored liver histological changes, ameliorated hepatocyte steatosis, and alleviated inflammatory cell infiltration. Consistent with the pathological changes, QSHY granules significantly reduced the elevated levels of liver triglycerides, and serum alanine aminotransferase, and it relieved hypercholesterolemia and insulin resistance in mice with HFHS-induced NAFLD. Furthermore, it corrected BCAA metabolic disorders in serum and feces and promoted the expression of BCAA catabolic genes in the eWAT of HFHS mice. QSHY granules also increased the expression of phosphorylated AMP-activated protein kinase (AMPK) protein, up-regulating the protein expression of the AMPK/SIRT1/UCP-1 pathway in the eWAT. Conclusion: QSHY granules improved hepatic steatosis and corrected the BCAA disorder in NAFLD mice, and the related mechanisms regulated the AMPK/SIRT1/UCP-1 pathway and promoted WAT browning. Keywords: nonalcoholic fatty liver disease, branched chain amino acids, white adipose tissue, browning, traditional Chinese medicine Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease worldwide. The incidence of NAFLD is increasing rapidly, with a global prevalence rate of 25.24%, and a prevalence rate as high as 29.2% in China. 1,2 Currently, NAFLD has surpassed viral hepatitis B as the chronic liver disease with the highest global incidence. 3 Despite this, there is no approved therapeutic drug for NAFLD treatment. Changes in dietary and exercise habits are commonly adopted as interventions; however, these interventions have the disadvantages, such as poor patient adherence and easy rebound of efficacy. Therefore, investigations into potentially safe and effective drugs that can be applied to NAFLD treatment are urgently needed. The mechanisms and heritability of NAFLD are complex, and adipocyte dysfunction is an important factor that influences the progression of NAFLD. In obesity, increased lipolysis of white adipose tissue (WAT) is an important source of peripheral and liver free fatty acids (FFAs) and that influences the metabolic network and the inflammation status in the liver. In contrast, brown adipose tissue (BAT) and beige adipocytes in WAT have positive effects on peripheral plasma metab -Abstract Truncated-